259 related articles for article (PubMed ID: 33925278)
1. Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study).
Calegari MA; Salvatore L; Di Stefano B; Basso M; Orlandi A; Boccaccino A; Lombardo F; Auriemma A; Zurlo IV; Bensi M; Camarda F; Ribelli M; Vivolo R; Cocomazzi A; Pozzo C; Milella M; Martini M; Bria E; Tortora G
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925278
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
3. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
4. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
Yaeger R; Kotani D; Mondaca S; Parikh AR; Bando H; Van Seventer EE; Taniguchi H; Zhao H; Thant CN; de Stanchina E; Rosen N; Corcoran RB; Yoshino T; Yao Z; Ebi H
Clin Cancer Res; 2019 Dec; 25(23):7089-7097. PubMed ID: 31515458
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
6. Focus on
Schietroma F; Anghelone A; Valente G; Beccia V; Caira G; Spring A; Trovato G; Di Bello A; Ceccarelli A; Chiofalo L; Perazzo S; Bensi M; Minucci A; Urbani A; Larocca LM; Basso M; Pozzo C; Salvatore L; Calegari MA; Tortora G
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473349
[No Abstract] [Full Text] [Related]
7.
Jones JC; Renfro LA; Al-Shamsi HO; Schrock AB; Rankin A; Zhang BY; Kasi PM; Voss JS; Leal AD; Sun J; Ross J; Ali SM; Hubbard JM; Kipp BR; McWilliams RR; Kopetz S; Wolff RA; Grothey A
J Clin Oncol; 2017 Aug; 35(23):2624-2630. PubMed ID: 28486044
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.
Xu T; Li J; Wang Z; Zhang X; Zhou J; Lu Z; Shen L; Wang X
Cancer Med; 2023 May; 12(9):10473-10484. PubMed ID: 36912150
[TBL] [Abstract][Full Text] [Related]
9. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
10. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer.
Johnson B; Loree JM; Jacome AA; Mendis S; Syed M; Morris Ii VK; Parseghian CM; Dasari A; Pant S; Raymond VM; Vilar E; Overman M; Kee B; Eng C; Raghav K; Kopetz S
JCO Precis Oncol; 2019; 3():. PubMed ID: 32914034
[TBL] [Abstract][Full Text] [Related]
11. Class 1, 2, and 3
Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
[TBL] [Abstract][Full Text] [Related]
12. A validated prognostic classifier for
Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
[TBL] [Abstract][Full Text] [Related]
13. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.
Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M;
BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148
[TBL] [Abstract][Full Text] [Related]
14. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
16. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.
Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C
Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Features and Prognosis of
Guan WL; Qiu MZ; He CY; Yang LQ; Jin Y; Wang ZQ; Li YH; Xu RH; Wang FH
Front Oncol; 2020; 10():563407. PubMed ID: 33330032
[No Abstract] [Full Text] [Related]
18. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
19. Atypical
Pietrantonio F; Yaeger R; Schrock AB; Randon G; Romero-Cordoba S; Rossini D; Fucà G; Ross JS; Kotani D; Madison R; Kim ST; Salvatore L; Raimondi A; Pagani F; Borelli B; Perrone F; Di Bartolomeo M; Miller VA; Ali SM; Lee J; Yoshino T; de Braud F; Falcone A; Hechtman JF; Cremolini C
JCO Precis Oncol; 2019 Dec; 3():1-11. PubMed ID: 35100719
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
